Jaguar Health, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved renewal of Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company's conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy. The renewal for conditional approval is in effect until December 21, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.18 USD | +5.88% | +14.72% | +18.89% |
1st Jan change | Capi. | |
---|---|---|
+18.89% | 49.72M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- JAGX Stock
- News Jaguar Health, Inc.
- FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs